stockrow
Saturday 7 November 2026
Export GHRS’s income statement to Excel — free account
GH Research PLC
GHRS Healthcare Biotechnology
- EPS
- −53.3%
- Free cash flow
- −66.6%
- Total debt
- −97.9%
Quarter to June 2026, against a year earlier
18.49
0.05
+0.27%
Follow GHRS
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
28.32 | 34.13 | 23.04 | 28.70 |
Net Debt/EBITDA |
17.50 | 16.87 | 14.32 | 18.73 | |
Debt/Assets |
0.07% | 0.05% | 0.03% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.98 | 0.87 | 0.56 | 0.99 | |
Capex/Depreciation |
(0.44) | (0.22) | (0.69) | (0.19) | |
Interest Coverage |
(788.81) | (185.74) | (223.20) | (234.40) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.22) | (0.20) | (0.17) | (0.23) | |
Cash per Share |
4.65 | 4.60 | 4.31 | 5.45 | |
Shareholders Equity per Share |
4.70 | 4.58 | 4.25 | 5.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.70 | 4.58 | 4.25 | 5.40 | |
Free Cash Flow |
(13.72) | (12.35) | (10.73) | (15.04) | |
Working Capital |
284.38 | 277.60 | 260.42 | 355.97 | |
Capital Expenditures |
(0.04) | (0.02) | (0.06) | (0.02) | |
Net Current Asset Value |
284.17 | 277.45 | 260.34 | 355.97 | |
| Other line items | |||||
Quick Ratio |
27.72 | 33.50 | 22.63 | 28.22 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.22) | (0.20) | (0.17) | (0.23) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
3.39 | 3.76 | 4.99 | 4.69 | |
Average Assets |
250.82 | 238.25 | 297.86 | 342.89 | |
Average Common Equity |
240.38 | 229.33 | 286.80 | 331.33 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates